HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Looks To Expand Consumer Biz After Consent Decree Obligations End

This article was originally published in The Rose Sheet

Executive Summary

J&J is “very excited about the possibility of consumer becoming a bigger part of our business,” CFO Caruso says, noting it hopes to grow the business organically and through acquisitions. But J&J first must complete its obligations under a consent decree related to manufacturing quality problems.

You may also be interested in...



Tylenol Relaunch Ads Harken To “Trusted” History

In online video ads for Tylenol, the firm says “for everything we do, we know you do so much more.” CFO Dominic Caruso says the ad campaign will reconnect the brand with consumers.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel